Therapeutic evaluation of compounds in the SCID-RA papillomavirus model.
A previous study by Kreider (Kreider et al., 1979) indicated that rabbit skin, which had been transplanted to immunodeficient nude mice, could be successfully infected with cottontail rabbit papillomavirus (CRPV). We have extended this observation in developing a rodent model for evaluation of compounds for activity against the papillomaviruses. In this model (called the SCID-Ra model), rabbit ear skin is transplanted to the dorsum of SCID mice and allowed to heal for 3 weeks. Infection with CRPV by scarification leads to the growth of warty lesions within 2 3 weeks in >95% of the animals. Topical and/or systemic therapy can be initiated at various times post infection (PI). Weekly lesion scores are recorded and compounds are evaluated for their ability to suppress wart growth when compared to untreated control mice. Ribavirin, which has had a suppressive effect both in the clinic for the treatment of respiratory papillomatosis and on the growth of warts in the rabbit back model, was evaluated and showed significant anti-proliferative activity with oral dosing. Both antiviral and antiproliferative compounds including podophyllin and 5-fluorouracil, which have been used clinically for the treatment of human papillomavirus (HPV) infections, were evaluated in this model. The anti-mitotic compound, Navelbine (vinorelbine tartrate), which is used for the treatment of non-small cell lung carcinoma was evaluated in this system and showed significant inhibition of wart growth with somewhat less topical cytotoxicity when compared to podophyllotoxin.
Lobe
D C
DC
Department of Virology, Glaxo Wellcome, Research Triangle Park, NC 27709, USA.
Kreider
J W
JW
Phelps
W C
WC
D000818:Animals; D000998:Antiviral Agents; D012777:Cottontail rabbit papillomavirus; D004195:Disease Models, Animal; D005260:Female; D051379:Mice; D016513:Mice, SCID; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits; D016038:Skin Transplantation; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000473:pathology; D014860:Warts / Q000188:drug therapy* / Q000473:pathology
D000998:Antiviral Agents